Why the study?
Does iproveratril alter peripheral vascular responses to vasoactive agents in canine models?
Does iproveratril alter peripheral vascular responses to vasoactive agents in canine models?
Iproveratril acts as a nonspecific antagonist of peripheral vascular reactivity, depressing responses to alpha, beta, and angiotensin receptor stimulants.
Answers are grounded in this paper and cite their sources.
May guide interpretation of canine vascular studies; leaves open translation to human therapy.
The effect of iproveratril (α-isopropyl- α-[(N-methyl-N-homoveratryl)-γ-aminopropyl]-3,4-dimethoxyphenolacetonitrile hydrochloride) on peripheral vascular responses to isoproterenol (ISO), norepinephrine (NE), angiotensin II (A), and nitroglycerin (GTN) was evaluated in the canine hindlimb and hindpaw preparations perfused with autologous blood at constant flow. Iproveratril (30–300 μg/kg intravenous) dilated the hindlimb and hindpaw perfused at constant flow. Responses to intra-arterial ISO, NE, and A were significantly reduced when evaluated 10 min after iproveratril. Iproveratril did not alter the vasodilator responses to GTN. These results show that iproveratril depresses the vascular responses of the hindlimb and hindpaw to stimulants of α and β adrenergic and angiotensin receptors and justify the conclusion that iproveratril is not a selective antagonist of peripheral β-receptors.
No takes yet. Share an insight, caveat, or question.
Greenberg et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: